This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

John H. Bauer, MD; Louise B. Jones, RN; Patricia Gaddy, RN

Arch Intern Med. 1984;144(2):308-312.

Abstract
• Indoramin hydrochloride is a new ₁-adrenoceptor antagonist. Eleven hypertensive men in whom the BP was normalized with indoramin underwent assessment of renal function, renal hemodynamics, and body fluid composition following short-term (three to six weeks), long-term (five to six months), and withdrawal (two weeks) therapy. Short-term indoramin therapy produced a 28% increase in glomerular filtration rate, a 24% increase in effective renal plasma flow, and a 31% decrease in renal vascular resistance. Although urine flow rate and free water clearance were unchanged, fractional sodium excretion decreased 38%. Long-term indoramin therapy was associated with qualitatively similar renal effects, but the changes did not achieve statistical significance. Plasma volume was increased only during short-term therapy; however, body weight was increased following both short- and long-term therapy. Indoramin effectively lowers BP without producing deleterious renal effects.

(Arch Intern Med 1984;144:308-312)

Author Affiliations
From the Medical (Dr Bauer) and Nursing (Mss Jones and Gaddy) Services, The Harry S Truman Memorial Veterans Hospital, and the Department of Medicine, University of Missouri Hospital and Clinics, Columbia, Mo.

Footnotes
Accepted for publication June 22, 1983.

Reprint requests to Medical Service (111-E), The Harry S Truman Memorial Veterans Hospital, Columbia, MO 65201 (Dr Bauer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?